Back to search results

my.naviGATE for Adolescents and Young Adults with Cancer

This study is testing a new mobile app called my.naviGATE. This app is designed to help adolescents and young adults (AYA) aged 15-24 who are currently undergoing cancer treatment for conditions like sarcoma or leukemia. The app offers personalized information about living with cancer after treatment, connects you with trained peer navigators (people who have been through similar experiences), and collects your feedback through surveys. Researchers want to see if using my.naviGATE helps you feel more involved in your health decisions and how easy and helpful the app is to use. The study is currently unclear about its recruitment status and plans to enroll about 143 participants.

Study design
This is a multi-center pilot study where about 143 participants will be randomly assigned to either use the my.naviGATE app or receive usual care. Randomization means you are placed into a group by chance.
What's involved
You would complete questionnaires or surveys. If you are in the my.naviGATE group, you would use the mobile app. Some participants may also have qualitative interviews with study staff.
Compensation
Not stated in the trial record.
Follow-up
Your progress will be assessed at baseline, 1 month after your cancer treatment ends, and 6 months after your cancer treatment ends.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07516353

my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults

Not Yet Recruiting
NAAges 15–24InterventionalHealth services
Dana-Farber Cancer Institute
~143 participants
Updated 2026-04-08 on ClinicalTrials.gov
What's tested:my.naviGATE Digital Tool

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Patient Activation Measure (PAM)-13 Score from Baseline to 6 Months Post-EOT
Measured over Assessed at baseline, 1-month post EOT (+2 months) and 6-months post EOT (+2 months)
+2 more outcomes measured

Conditions

Sarcoma
Osteosarcoma
Ewing Sarcoma
Rhabdomyosarcoma
Acute Myeloid Leukemia
Aml
ALL
Medulloblastoma
Acute Lymphoblastic Leukemia ,Lymphomas

Explore related trials

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaEwing SarcomaHematologic NeoplasmHodgkin's GranulomaMature B-Cell Non-Hodgkin LymphomaMedulloblastomaOsteosarcomaRhabdomyosarcomaSolid Neoplasm

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Katie Greenzang, MD · PRINCIPAL_INVESTIGATOR · Dana-Farber Cancer Institute

Who to contact

Katie Greenzang, MD
[email protected]
6176325992
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients aged 15-24 who are currently undergoing cancer treatment at one of the three participating sites: DFCI, CNH, or RPOCH.
Patients must have initiated and be actively receiving cancer directed therapy for a newly diagnosed cancer.
Patients must be actively receiving cancer directed therapy, between the time of diagnosis and end of therapy for the following diagnoses: 1) Sarcomas: including osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma; 2) Acute Myeloid Leukemia (AML); 3) Acute Lymphoblastic Leukemia/Lymphoma (ALL); 4) Hodgkin and mature B-cell Lymphomas; and 5) Medulloblastoma.
Patients whose treatment includes alkylators, anthracyclines, and/or radiation.

Exclusion

Patients who are unwilling to give informed consent or assent to participate will be excluded. For patients under 18, patients whose guardians do not give informed consent will be excluded.
Patients with no chance of cure as identified by the AYA's physician, will be excluded given that issues of survivorship are not relevant and may be distressing to this population. Similarly, patients with relapsed or refractory disease will also be excluded.
Patients who are non-English-speaking and -reading will be excluded as the digital tool is being developed initially in English.
We will seek physician permission before offering enrollment to patients. If the provider team requests that the patient not be approached to participate, the patient will be excluded.

What this trial measures

  • Change in Patient Activation Measure (PAM)-13 Score from Baseline to 6 Months Post-EOTAssessed at baseline, 1-month post EOT (+2 months) and 6-months post EOT (+2 months)

    The Patient Activation Measure (PAM-13) is a validated, self-administered questionnaire assessing knowledge, skills, and confidence for self health-management. It has 13 items with a standardized score from 1-100 derived from 4-point Likert scale answer choices ranging from "Disagree Strongly" to "Agree Strongly;" a higher standardized score represents greater activation.

  • Application (App) Feasibility Rate (Intervention Group)Assessed at 1-month post EOT (+2 months) and 6-months post EOT (+2 months)

    App feasibility rate is the proportion of participants in the intervention group ever using the my.naviGATE app. Usage metrics are collected through the app development platform.

  • Application (App) Acceptability Rate (Intervention Group)Assessed at 1-month post EOT (+2 months) and 6-months post EOT (+2 months)

    App acceptability will be assessed in the intervention group with an adapted acceptability electronic (E)-scale for web-based PROs in cancer care. Acceptability rate is the proportion of patients achieving acceptability on the 3-item scale, each using the 5-point Likert scale (1=lowest acceptability/not acceptable to 5 highest acceptability). The score ranges from 3-15 points and a score of 12 or higher indicates acceptability. (Tariman et al. Appl Nurs Res. 2011)